Every 10-Q that Cerus Corp (CERS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CERS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CERS filings page.
Cerus Corporation, developer of the INTERCEPT Blood System, reported higher product revenue while remaining loss-making for the quarter ended June 30, 2026. Product revenue was $57,441 (in thousands), up from $52,445 (in thousands) a year earlier, with additional government contract revenue of $5,862 (in thousands).
Loss from operations narrowed to $1,858 (in thousands), and net loss attributable to Cerus was $2,940 (in thousands), or $0.01 per basic and diluted share, compared with $0.03 a year earlier. Cash and cash equivalents were $17,980 (in thousands) and short-term investments $38,284 (in thousands). Total debt principal was $65,088 (in thousands), comprising a $35,000 (in thousands) term loan at an interest rate of approximately 9.4% and $30,088 (in thousands) outstanding under a revolving credit facility. Cerus also highlighted substantial non-dilutive funding capacity through BARDA and DoD contracts supporting red blood cell and cryoprecipitate programs.
Cerus Corporation reported improved Q1 2026 results, with revenue growing and losses narrowing. Product revenue reached $53.7 million for the three months ended March 31, 2026, up from $43.2 million a year earlier, while government contract revenue was $6.2 million versus $5.6 million.
Loss from operations narrowed to $0.4 million, compared with $5.9 million in the prior-year quarter. Net loss attributable to Cerus was $1.6 million, or $0.01 per share, better than the $7.7 million net loss and $0.04 loss per share a year ago.
Cerus ended the quarter with $27.9 million in cash and cash equivalents, $52.6 million in short-term investments and $0.6 million of restricted cash. Debt totaled $84.9 million, including $52.4 million classified as current. Operating activities used $3.0 million of cash, while investing activities provided $9.9 million mainly from investment maturities.
Cerus Corporation (CERS) filed its Q3 2025 10‑Q, showing higher sales and near breakeven results. Product revenue reached $52.7 million, up from $46.0 million a year ago, and government contract revenue was $7.5 million versus $4.6 million. Gross profit on product revenue was $28.1 million compared with $26.2 million. The quarter’s net loss attributable to Cerus was $19 thousand, or $0.00 per share.
Operating expenses rose with R&D at $15.8 million and SG&A at $18.6 million. For the nine months, product revenue was $148.4 million and government contract revenue was $20.8 million, with a net loss of $13.4 million. Cash and cash equivalents were $15.7 million and short‑term investments $62.8 million. Total debt was $84.9 million, with $36.2 million classified as current and $48.7 million as non‑current. Inventories increased to $68.1 million, including $53.1 million current. Net cash used in operating activities for the nine months was $1.4 million. As of October 17, 2025, common shares outstanding were 192,087,501. No shares were sold under the at‑the‑market program, leaving approximately $96.8 million available.